Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

6 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Components of Stock-Based Compensation Expense

Compensation Expense. The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, compensation expense for the ESPP and warrants to non-employees for the six months ended June 30, 2013 and 2012, and from the period June 28, 2006 (date of inception) to date.


	For the six months ended June 30,				Period from June 28, 2006 (date of inception) to June 30,
($ in thousands)	2013		2012		2013
Employee awards	$	2,016	$	812	$	5,222
Non-employee awards		652		242		4,065
Non-employee warrants		138		164		1,031

Total stock-based compensation expense	$	2,806	$	1,218	$	10,318

Summary of Stock Option Activity

The following table summarizes stock option activity since December 31, 2012:


	Outstanding Options							Weighted Average Remaining Contractual Life (in years)
($ in thousands except per share amounts)	Number of Shares			Weighted Average Exercise Price		Total Weighted Average Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
At December 31, 2012		2,519,070		$	3.37	$	2,860		8.5
Options granted		2,031,590			6.07
Options exercised		(245,157	)		1.56
Options cancelled		(20,000	)		1.93

At June 30, 2013		4,285,503		$	4.77	$	16,434		8.9

Options vested and expected to vest		4,285,503		$	4.77	$	16,434		8.9
Options vested and exercisable		1,047,053		$	2.84	$	6,031		7.9